Ampio Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Selling, General & Admin	7.08	11.47	8.67	6.66	5.95
Research & Development	2.44	8.92	11.9	9.17	12.62
Operating Expenses	9.52	20.38	20.57	15.83	18.58
Operating Income	-9.52	-20.38	-20.57	-15.83	-18.58
Interest & Investment Income	0.35	0.22	0	0.01	0.08
Other Non Operating Income (Expenses)	0.31	5.76	3.49	-0.54	4.87
EBT Excluding Unusual Items	-8.87	-14.4	-17.08	-16.37	-13.63
Gain (Loss) on Sale of Assets	-0.06	-	-	-0.07	-
Asset Writedown	-	-1.94	-	-	-
Other Unusual Items	0.29	-	-	0.54	-
Pretax Income	-8.63	-16.34	-17.08	-15.89	-13.63
Earnings From Continuing Operations	-8.63	-16.34	-17.08	-15.89	-13.63
Net Income to Company	-8.63	-16.34	-17.08	-15.89	-13.63
Net Income	-8.63	-16.34	-17.08	-15.89	-13.63
Net Income to Common	-8.63	-16.34	-17.08	-15.89	-13.63
Shares Outstanding (Basic)	1	1	1	1	0
Shares Outstanding (Diluted)	1	1	1	1	0
Shares Change (YoY)	7.50%	10.30%	18.58%	31.81%	18.20%
EPS (Basic)	-10.66	-21.68	-25.70	-27.59	-31.31
EPS (Diluted)	-10.66	-29.32	-30.10	-27.59	-42.32
Free Cash Flow	-8.56	-21.13	-14.19	-14.79	-15.41
Free Cash Flow Per Share	-10.57	-28.04	-20.76	-25.67	-35.24
EBITDA	-9.39	-19.33	-19.48	-14.66	-17.3
D&A For EBITDA	0.13	1.05	1.09	1.18	1.27
EBIT	-9.52	-20.38	-20.57	-15.83	-18.58

Source: S&P Global Market Intelligence. Standard template. Financial Sources.